Mazdutide
Investigational GLP-1/glucagon dual receptor agonist (an OXM analog) in late-stage development, primarily in China. Phase 3 data show meaningful weight loss with the added glucagon-driven energy expenditure component.
01 Overview
Mazdutide (IBI362/LY3305677) is a peptide dual agonist of the GLP-1 and glucagon receptors, based on the oxyntomodulin (OXM) backbone. The glucagon component is intended to increase energy expenditure and improve hepatic fat, while GLP-1 drives appetite suppression.
It is being developed by Innovent in China and has reported positive Phase 3 results (GLORY-1) for obesity, with regulatory review under way in China. Human data are growing but far less extensive than for approved GLP-1 agonists.
02 Mechanism
Co-agonises GLP-1 and glucagon receptors; GLP-1 suppresses appetite while glucagon signalling raises energy expenditure and reduces hepatic fat.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Lower dose | 3 mg/wk | SubQ | Studied in diabetes cohorts |
| Trial dose | 4–6 mg/wk | SubQ | Doses studied in Phase 3 obesity trials |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Weight lossReported in Phase 3 GLORY-1 at higher doses. | ~11-14% body weight | Clinical | |
| Reduced hepatic fatGlucagon component improves hepatic steatosis markers. | Significant liver fat reduction | Clinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Gastrointestinal upsetNausea, diarrhoea and decreased appetite during titration. | Moderate | Very common | Clinical | |
| Increased heart rateModest heart-rate rise associated with glucagon agonism. | Mild | Common | Clinical |